Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

[Effects, safety and cost-benefit analysis of Down syndrome screening in first trimester].

Shengmou L, Min C, Chenhong W, Shengli L, Jiansheng X, Hui Y, Dinghao L, Xiaoxia W, Wei W, Hongyun Z, Haiyan T.

Zhonghua Fu Chan Ke Za Zhi. 2014 May;49(5):325-30. Chinese.

PMID:
25030727
2.
3.

[Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].

Borowski D, Czuba B, Cnota W, Hincz P, Czekierdowski A, Gajewska J, Jaczyńska R, Ceran A, Włoch A, Wyrwas D, Wiełgoś M, Szymusik I, Szaflik K, Sodowski K.

Ginekol Pol. 2007 May;78(5):384-7. Polish.

PMID:
17867331
4.

Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.

Soergel P, Pruggmayer M, Schwerdtfeger R, Muhlhaus K, Scharf A.

Fetal Diagn Ther. 2006;21(3):264-8.

PMID:
16601335
5.

[Results of prenatal screening for fetal chromosome abnormality during the first trimester pregnancy in Guangzhou].

Xu Z, Li B, Liao C, Sun Q, Bai X, Li D.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2014 Oct;31(5):632-5. doi: 10.3760/cma.j.issn.1003-9406.2014.01.021. Chinese.

PMID:
25297598
6.

A cost-effectiveness analysis of prenatal screening strategies for Down syndrome.

Odibo AO, Stamilio DM, Nelson DB, Sehdev HM, Macones GA.

Obstet Gynecol. 2005 Sep;106(3):562-8. Erratum in: Obstet Gynecol. 2006 Jan;107(1):209.

PMID:
16135588
7.

Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.

Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.

Ultrasound Obstet Gynecol. 2006 Feb;27(2):151-5.

8.

Clinical first-trimester routine screening for Down syndrome in singleton pregnancies in northern Finland.

Valinen Y, Rapakko K, Kokkonen H, Laitinen P, Tekay A, Ahola T, Ryynanen M.

Am J Obstet Gynecol. 2007 Mar;196(3):278.e1-5.

PMID:
17346554
9.

Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies.

Evans MI, Sonek JD, Hallahan TW, Krantz DA.

Ultrasound Obstet Gynecol. 2015 Jan;45(1):74-83. doi: 10.1002/uog.14693.

10.

Analysis of the impact of PAPP-A, free β-hCG and nuchal translucency thickness on the advanced first trimester screening.

Berktold L, von Kaisenberg CS, Hillemanns P, Vaske B, Schmidt P.

Arch Gynecol Obstet. 2013 Mar;287(3):413-20. doi: 10.1007/s00404-012-2585-y. Erratum in: Arch Gynecol Obstet. 2013 Aug;288(2):467. V Kaisenberg, C [corrected to von Kaisenberg, C S].

PMID:
23080546
11.

Comparison of first-trimester contingent screening strategies for Down syndrome.

Sahota DS, Leung TY, Chan LW, Law LW, Fung TY, Chen M, Lau TK.

Ultrasound Obstet Gynecol. 2010 Mar;35(3):286-91. doi: 10.1002/uog.7549.

13.

Prospective validation of first-trimester combined screening for trisomy 21.

Kagan KO, Etchegaray A, Zhou Y, Wright D, Nicolaides KH.

Ultrasound Obstet Gynecol. 2009 Jul;34(1):14-8. doi: 10.1002/uog.6412.

14.

First-trimester combined screening for trisomy 21 in a predominantly Chinese population.

Leung TY, Chan LW, Leung TN, Fung TY, Sahota DS, Spencer K, Lau TK.

Ultrasound Obstet Gynecol. 2007 Jan;29(1):14-7.

15.

First-trimester or second-trimester screening, or both, for Down's syndrome.

Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium..

N Engl J Med. 2005 Nov 10;353(19):2001-11.

16.

Maternal weight and ethnic adjustment within a first-trimester Down syndrome and trisomy 18 screening program.

Krantz DA, Hallahan TW, Macri VJ, Macri JN.

Prenat Diagn. 2005 Aug;25(8):635-40.

PMID:
16049986
17.

First-trimester screening for trisomy 21 in twin pregnancy: does the addition of biochemistry make an improvement?

Goncé A, Borrell A, Fortuny A, Casals E, Martínez MA, Mercadé I, Cararach V, Vanrell JA.

Prenat Diagn. 2005 Dec;25(12):1156-61.

PMID:
16231401
18.

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.

Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 Sep;32(4):488-92. doi: 10.1002/uog.6123.

19.

[Maternal biochemical screening -- an approach for genetic prevention. part 1. first and second trimester screening].

Angelova L, Gadancheva V, Konstantinova D, Stoianova M, Hachmerian M, Yakov B, Kremenski I.

Akush Ginekol (Sofiia). 2013;52(5):8-13. Bulgarian.

PMID:
24501862
20.

First trimester predictors of adverse pregnancy outcomes.

Brameld KJ, Dickinson JE, O'Leary P, Bower C, Goldblatt J, Hewitt B, Murch A, Stock R.

Aust N Z J Obstet Gynaecol. 2008 Dec;48(6):529-35. doi: 10.1111/j.1479-828X.2008.00912.x.

PMID:
19133038
Items per page

Supplemental Content

Support Center